Clinical Trial Update: NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating NBTXR3 with radiation therapy and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• NBTXR3 (hafnium oxide nanoparticles)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: TERMINATED